Clinical Trials Logo

Basic Science clinical trials

View clinical trials related to Basic Science.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04443647 Completed - Basic Science Clinical Trials

Influence of Oxytocin on Approach-avoidance Tendencies to Social and Non-social Stimuli

Start date: December 15, 2018
Phase: N/A
Study type: Interventional

In this study, a randomized, placebo-controlled between-subject design is adopted to investigate the effect of a single-dose of intranasally administered OT on approach-avoidance related motivational tendencies during the processing of a series of social and non-social, positively and negatively valenced stimuli. To obtain a behavioral measure of approach-avoidance tendencies, participants will be able to control the viewing time of the presented stimuli, by pressing 'up' or 'down' on a keyboard. During stimulus presentation neurophysiological recordings will be performed to obtain a neural measure of approach-avoidance motivational tendencies, based on electroencephalographic recordings (EEG: frontal alpha asymmetry). Also assessments of autonomic arousal, based on skin conductance recordings will be collected.

NCT ID: NCT03541473 Completed - Basic Science Clinical Trials

Phosphate Metabolites in Brain of Humans Aged 50+

Start date: May 14, 2018
Phase: N/A
Study type: Interventional

The objective of this research project is to determine in elderly subjects (>50 year old) by 31P-MRS the brain concentration of phosphorous metabolites species and fluxes, before and after consumption of 2 commercially available oral nutrition products

NCT ID: NCT01860287 Completed - Basic Science Clinical Trials

The Effects of Buprenorphine on Responses to Verbal Tasks

Start date: September 2013
Phase: Early Phase 1
Study type: Interventional

In this study, the investigators will examine the effects of buprenorphine, as compared to placebo, upon physiological, subjective, and hormonal responses to a stressful speech task and a non-stressful control task in healthy adults. There is strong evidence in support of the role of endogenous opioids and opiates in mediating social behavior in humans and other animals, and particularly, in social distress. Recently it has been shown that buprenorphine, a partial mu-opioid agonist, reduces sensitivity to recognition of fearful facial expressions in humans. Here, the investigators propose to further explore the role of the opioid system in mediating stress responses in humans through the use of buprenorphine. The investigators hypothesize that buprenorphine with reduce both physiological and subjective measures of stress.